Company intelligence / Profile preview

Acumen Pharma Consulting

Charlottesville, Virginia, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Acumen Pharmaceuticals' lead candidate, sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers, has completed a positive Phase 1 trial (INTERCEPT‐AD) in early Alzheimer's disease and initiated a Phase 2 study (ALTITUDE‐AD). Biomarker results from the Phase 1 trial have been published in The Journal of Prevention of Alzheimer's Disease[4][3].

Therapeutic areas: Neurology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Acumen Pharma Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acumen Pharma Consulting.

Explore the full profile